Drug diversion mitigation in healthcare is often framed as a surveillance issue—auditing dispensing records, reconciling discrepancies, and tightening controlled-substance accountability. Those measures are essential, but they represent only one layer of organizational risk management.
In a Rxpert Solutions podcast interview, we sat down with Dr. Alan Goldhamer, co-founder of True North Health Center, to explore a critical but often overlooked contributor to opioid exposure: chronic pain driven by systemic inflammation. The discussion challenges traditional thinking around pain management and opioid reliance—and highlights why diversion mitigation benefits from a broader systems perspective.
National data underscores why this matters: chronic pain affects a significant portion of U.S. adults, and opioid exposure remains a major public health issue.
What’s often missed in diversion strategy conversations is this:
Chronic pain is frequently the upstream driver of opioid exposure—and long-term exposure increases healthcare diversion risk.
If mitigation efforts focus only on detection, organizations may overlook a major source of internal vulnerability.
The Overlooked Driver of Healthcare Diversion Risk
Many cases of opioid dependence do not begin with recreational misuse. They begin with legitimate prescriptions for unresolved pain. When pain persists, medication reliance can escalate over time—creating predictable risk patterns in high-access environments.
From a systems lens, this creates dual exposure:
- Patient-level opioid dependency risk
- Workforce-level diversion vulnerability (access + stress + fatigue + exposure)
That’s why drug diversion mitigation cannot be treated as only a “compliance audit function.” It must also account for the conditions that increase opioid reliance in the first place.
Start with a Clear Risk Picture
If you’re unsure where your facility’s biggest vulnerabilities sit, begin with an on-site, workflow-focused assessment.
→ Explore On-Site Drug Diversion Risk Assessment.
Chronic Pain, Inflammation, and Opioid Dependence
Inflammation is increasingly recognized as a contributor to chronic pain burden. For example, research has found associations between C-reactive protein (CRP) and chronic pain, supporting the concept of an underlying inflammatory mechanism in at least some patient populations.
Why does this matter for drug diversion mitigation?
Because inflammation-driven pain commonly leads to:
- Longer duration of opioid therapy
- Higher cumulative exposure
- More frequent refills or dose escalation
- Increased operational “touchpoints” across dispensing, wasting, and documentation
And from a risk standpoint, higher exposure environments can amplify vulnerability.
A practical systems takeaway is:
If inflammation decreases, pain burden may decrease.
If pain burden decreases, opioid reliance may decrease.
If opioid reliance decreases, organizational diversion exposure may decrease.
Why Monitoring Alone Is Not a Complete Drug Diversion Mitigation Strategy
Most diversion programs emphasize:
- Automated dispensing cabinet monitoring
- Waste reconciliation
- Outlier detection
- Investigation workflows
- Documentation defensibility
These pillars are non-negotiable.
But mitigation that is only detection-oriented remains reactive. Risk also emerges from:
- Chronic pain among healthcare workers
- Shift fatigue and sleep disruption
- Burnout and psychological stress
- Easy access combined with repeated exposure
Compliance systems detect discrepancies. They don’t reduce the upstream conditions that increase vulnerability.
A Root-Cause Model of Opioid Risk Mitigation
In the podcast conversation, Dr. Goldhamer described clinical observations from decades of working with chronic inflammatory conditions—often using nutrition-first strategies, structured fasting approaches (clinically supervised in their setting), and sleep optimization.
This is not about replacing medical pain management or compliance controls.
It’s about strengthening mitigation strategy design with a broader understanding of opioid exposure drivers. Organizations that incorporate upstream awareness are better positioned to:
- Support safer prescribing ecosystems (within clinical governance)
- Align workforce support with risk realities
- Reduce cumulative exposure where clinically appropriate
- Improve the overall resilience of the controlled-substance system
Strengthen Mitigation Where It Starts
Diversion mitigation works best when policy, culture, monitoring, and operational realities align.
→ Read our perspective on Mitigating Diversion.
Sleep, Fatigue, and Medication Reliance
Sleep disruption matters because it affects pain sensitivity and coping capacity. Chronic pain and poor sleep often reinforce one another, and when sleep deteriorates, medication reliance can increase—especially in high-stress, shift-based roles.
From a mitigation standpoint, this isn’t “soft.” It’s systemic risk management:
- fatigue increases errors,
- stress increases vulnerability,
- exposure increases opportunity.
Drug diversion mitigation improves when leaders recognize these reinforcing loops—not just the endpoint discrepancy.
Building a Comprehensive Drug Diversion Mitigation Framework
A mature mitigation framework integrates:
- Monitoring analytics and alert governance
- Clear escalation/investigation workflows
- Policy clarity and documentation defensibility
- Leadership accountability and consistent review
- Culture-driven reporting and staff support
- Systems-level understanding of opioid exposure drivers
Because diversion risk is not just a compliance issue.
It’s a systems issue.
Get a Mitigation Plan You Can Defend
If you need executive-ready clarity on where your controlled substance vulnerabilities actually live—and what to do next—start here:
→ Request a Free 30-Minute Drug Diversion Risk Assessment.
